Charles A. O’Brien

Federal Grant PI High Impact

Professor of Medicine

University of Arkansas for Medical Sciences

faculty

Internal Med, College of Medicine

64 h-index 168 pubs 17,330 cited

Research Areas

Bone Metabolism and Diseases Osteoporosis Research Mesenchymal stem cell research Microbial infections and disease research Cancer-related molecular mechanisms research Immune Cell Function and Interaction Health and Medical Research Impacts

Links

ORCID Google Scholar Lab Website UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Charles A. O’Brien is a Professor of Medicine in the Department of Internal Medicine at the University of Arkansas for Medical Sciences. His research focuses on the cellular and molecular mechanisms underlying bone remodeling and skeletal development. Dr. O’Brien's work investigates the role of specific cell types, such as osteocytes and osteoclasts, in bone health and disease, including conditions like osteomyelitis and bone loss associated with cancer metastasis.

He has served as Principal Investigator (PI) on multiple federal grants, including two from the National Institutes of Health (NIH): the Center for Musculoskeletal Disease Research (CMDR) funded by the National Institute of General Medical Sciences for $2,295,000, and Osteocyte Control of Bone Remodeling funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases for $300,960. He also served as Co-PI on a grant from the NIH/National Institute on Aging titled "Different consequences of cellular aging in cortical versus cancellous bone" for $375,899.

Dr. O’Brien has published extensively on these topics, with 168 total publications and a citation count of over 17,330, reflected in his h-index of 64. His recent publications explore topics such as the NAD salvage pathway in mesenchymal cells, the identity of mesenchymal cell types in bone, and the use of CRISPR interference for cell type specificity. He actively collaborates with researchers at the University of Arkansas for Medical Sciences, including Elena Ambrogini, Olivia Reyes‐Castro, Maria Almeida, and Hayley M. Sabol.

Metrics

h-index: 64
Publications: 168
Citations: 17,330

Selected Publications

The Aging Landscape by <scp>scRNAseq</scp> of Mesenchymal Lineage Cells in Mouse Bone (2025) DOI
Mechanisms of mitochondrial reactive oxygen species action in bone mesenchymal cells (2025) DOI
Potent suppression of bone remodeling by denosumab does not blunt the anabolic response to romosozumab in mice (2025) DOI
A new <i>Col1a1</i> conditional knock-in mouse model to study osteogenesis imperfecta (2024) DOI
Denosumab stimulates spermatogenesis in infertile men with preserved Sertoli cell capacity (2024) DOI
RANKL-mediated osteoclast formation is required for bone loss in a murine model of Staphylococcus aureus osteomyelitis (2024) DOI
A New Mouse Model to Dissect the Contribution of Intrinsic Lung Defects Versus Extrinsic Skeletal Defects to Impaired Lung Function in Osteogenesis Imperfecta (2024) DOI
Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis (2024) DOI
Refining the identity of mesenchymal cell types associated with murine periosteal and endosteal bone (2024) DOI
A framework for defining mesenchymal cell types associated with murine periosteal and endosteal bone (2023) DOI
OR27-02 The Bone Anabolic Effect Of An Antibody Blocking Oxidized Phospholipids Is Associated With An Increase In Wnt10b In Osteoblasts. (2023) DOI
Retraction notice to “Deletion of the scavenger receptor Scarb1 in myeloid cells does not affect bone mass” [Bone 170(2023) 116702] (2023) DOI
Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation (2023) DOI
CRISPR interference provides increased cell type-specificity compared to the Cre-loxP system (2023) DOI
The NAD salvage pathway in mesenchymal cells is indispensable for skeletal development in mice (2023) DOI

Federal Grants 3 $2,971,859 total

NIH/National Institute on Aging Co-PI Apr 2021 - Dec 2026

Different consequences of cellular aging in cortical versus cancellous bone- Resubmission

National Institute on Aging $375,899 R01

NIH/National Institute of General Medical Sciences Contact PI Feb 2018 - Jan 2028

Center for Musculoskeletal Disease Research (CMDR)

National Institute of General Medical Sciences $2,295,000 P20

NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases Contact PI Sep 2003 - Mar 2027

Osteocyte Control of Bone Remodeling

National Institute of Arthritis and Musculoskeletal and Skin Diseases $300,960 R01

Grants & Funding

Center for Musculoskeletal Disease Research (CMDR) NIH/Nat. Inst. of General Medical Sciences Principal Investigator
Center for Musculoskeletal Disease Research (COBRE) NIH/Nat. Inst. of General Medical Sciences Principal Investigator
In Vivo Regulation of IL6 and IL6R Gene Expression NIH/Nat. Inst. of Arthritis & Musculoskeletal & Skin Diseases Principal Investigator
ABI C. OBrien NIH COBRE FY26 Y4 State of Arkansas Principal Investigator
Osteocyte Control of Bone Remodeling NIH/Nat. Inst. of Arthritis & Musculoskeletal & Skin Diseases Principal Investigator
RANKL and Lymphocyte Mediated Bone Loss Veterans Administration Principal Investigator
Center for Studies of Host Response to Cancer Therapy NIH Co-Investigator
IN VIVO REGULATION OF IL6 AND IL6R GENE EXPRESSION NIH Principal Investigator